Company Analysis

Immuneering Corporation (IMRX)

Nasdaq: IMRX · Pharmaceutical Preparations · Cambridge, MA · filing with the SEC since 2019
Grade4.9
◀ Past 4.1● Present 5.7▶ Future 4.6
4 est.

Who runs Immuneering Corporation

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Zeskind Benjamin J.
PRESIDENT AND CEO. First filing Jul 2021, latest Jun 24, 2026, 7 filings in all.
Officers reporting now
8
of 14 people with a filing in the last fifteen months
Directors reporting now
6
17 people on the record since 2021
Officerssales are open-market, Nov 9, 2025 to Nov 9, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Gengos AndrewChief Financial OfficerJul 2026Jul 17, 2026none
Zeskind Benjamin J.PRESIDENT AND CEOJul 2021Jun 24, 2026none
Hall Brett MatthewCHIEF SCIENTIFIC OFFICERJul 2021Jun 16, 2026none
Neufeld Leah RCHIEF PEOPLE OFFICEROct 2022Mar 17, 2026none
Bookman MichaelCHIEF LEGAL OFFICER, SECRETARYJul 2021Feb 5, 2026none
Brakewood Harold EugeneChief Business OfficerApr 2023Feb 5, 2026none
Matushansky IgorChief Medical OfficerMar 2025Feb 5, 2026none
Morales MallorySVP Finance, CAOAug 2022Feb 5, 2026none
Directorssales are open-market, Nov 9, 2025 to Nov 9, 2026
NameRoleFirst filingLatest filingSales, 12 months
Bogle Grant C.directorNov 2026Nov 9, 2026none
Carpenter Robert JdirectorJul 2021Jun 11, 2026none
Feinberg PeterdirectorJul 2021Jun 11, 2026none
Hausman DianadirectorJan 2022Jun 11, 2026none
Keating LauriedirectorJul 2021Jun 11, 2026none
Schall Thomas J.directorMar 2024Jun 11, 2026none
Earlier names on the record7, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton IMRX · research, not advice